|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| Non-controlled/non-affiliated investments, at fair value | ||||||||||||||
| Non-affiliated | ||||||||||||||
| Total non-controlled/non-affiliated investments, at fair value | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Subscription receivable | ||||||||||||||
| Restricted cash | ||||||||||||||
| Interest receivable | ||||||||||||||
| Interest and dividends receivable | ||||||||||||||
| Principal receivable | ||||||||||||||
| Unrealized appreciation on forward contracts | ||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||
| Total assets | ||||||||||||||
| LIABILITIES | ||||||||||||||
| Credit facility | ||||||||||||||
| SPV I Facility | ||||||||||||||
| SPV II Facility | ||||||||||||||
| Collateralized Loan Obligations | ||||||||||||||
| Subscription Facility | ||||||||||||||
| Revolving Credit Facility | ||||||||||||||
| Total credit facility | ||||||||||||||
| Unsecured Notes | ||||||||||||||
| Loan repurchase obligations | ||||||||||||||
| Deferred financing costs net of accumulated amortization | ||||||||||||||
| Total debt, net of financing costs | ||||||||||||||
| Payable for investments purchased | ||||||||||||||
| Interest payable | ||||||||||||||
| Distributions payable | ||||||||||||||
| Income based incentive fee payable | ||||||||||||||
| Management fees payable | ||||||||||||||
| Capital gains incentive fee payable | ||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||
| Accrued professional fees | ||||||||||||||
| Due to affiliates | ||||||||||||||
| Financing costs payable | ||||||||||||||
| Unrealized depreciation on forward contracts | ||||||||||||||
| Total liabilities | ||||||||||||||
| NET ASSETS | ||||||||||||||
| Preferred Stock, par value $0.001 (0 and 250 shares authorized and outstanding, respectively) | ||||||||||||||
| Paid-in capital in excess of par value of Preferred Stock | ||||||||||||||
| Common stock, par value $0.001 (200,000,000 shares authorized, 149,006,848 and 138,244,276 shares issued and outstanding, respectively) | ||||||||||||||
| Paid-in capital in excess of par value | ||||||||||||||
| Distributable earnings (accumulated losses) | ||||||||||||||
| Total net assets | ||||||||||||||
| Net asset value per common share |
Loading...
